Research programme: bispecific antibody therapeutics - Merus/Ono Pharmaceutical

Drug Profile

Research programme: bispecific antibody therapeutics - Merus/Ono Pharmaceutical

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merus; Ono Pharmaceutical
  • Class Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 19 Sep 2017 Merus has patent protection for Biclonics® technology in USA
  • 22 Aug 2017 Merus has patent protection for Biclonics® technology in USA
  • 19 Oct 2016 Merus signs additional agreement with Ono Pharmaceutical for CMC activities and receives milestone payment for bispecific antibody therapeutic development in Autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top